Recent Articles from GlobeNewswire

TORONTO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Clip Money Inc. (TSX-V: CLIP) (OTCQB: CLPMF) (“Clip Money” or the “Company”), a company that operates a multi-bank self-service deposit system for businesses, is pleased to announce that it is has secured a CAD$3 million loan (the "BDC Loan") from Business Development Bank of Canada’s (“BDC”) Growth and Transition Capital team.

AUSTIN, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company democratizing access to life insurance, today announced a partnership with Aflac Incorporated (NYSE: AFL), a leading provider of supplemental health insurance in the U.S., to expand access to Aflac’s supplemental insurance policies through Ethos’s digital distribution platform. The collaboration launches with Aflac’s cancer insurance, now available alongside Ethos’s life insurance offerings, expanding the range of protection options available through Ethos’s digital platform.

--Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals across multiple OA cohorts and real-world registries--

BLOOMINGTON, Ill., Dec. 18, 2025 (GLOBE NEWSWIRE) -- HBT Financial, Inc. (NASDAQ: HBT) (the “Company” or “HBT Financial”) announced today that its Board of Directors has approved a new stock repurchase program (the “Program”) that takes effect upon the expiration of the Company’s current stock repurchase program on January 1, 2026. The Company will not execute additional repurchases under the current program after January 1, 2026. The new Program authorizes the Company to repurchase up to $30 million of its common stock.

WATERTOWN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced a pipeline update, including a review of recent data for its INDUKINE™ programs, and a business overview of its priorities for 2026 that includes a focus on the Company’s highly differentiated INDUCER T cell engager platform. The Company is seeking strategic partnerships for further development of the promising WTX-124 and WTX-330 INDUKINE programs, informed by additional data from ongoing studies.

LONDON and CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare and prevalent ocular diseases, today announced that Lance Baldo, M.D., Chief Executive Officer of Beacon Therapeutics, will present a company overview at the 44th Annual JP Morgan Healthcare Conference being held January 12-15, 2025 in San Francisco, US.

LOS ANGELES, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Custom Ink, the online leader in custom products and apparel for organizations, groups, and businesses announced today that it has selected Innovative Partnerships Group as its agency to help build and expand its sponsorship and partnership vertical within the sports, entertainment, and university industries.

New Stripe Agentic Commerce Suite integration will give BigCommerce merchants seamless access to AI-driven discovery, checkout and payments with minimal operational change

NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines to treat brain disorders and symptoms caused by excess neural excitability, today announced results from its Phase 1 study of OV350, the first-ever KCC2 direct activator known to be dosed in humans. The study met its primary objectives to evaluate safety, tolerability and pharmacokinetics. Results from this intravenous program support the advancement of the Company’s portfolio of oral KCC2 direct activators into the clinic.

Latest acquisition adds Streamline's purpose-built special district website solution and PDF-to-HTML accessibility technology to the Civic Impact Platform

MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the dosing of the first patient with SAB-142 in the Phase 2b registrational SAFety and Efficacy of human anti-thymocyte immunoGlobUlin SAB-142 ARresting progression of type 1 Diabetes (SAFEGUARD) clinical trial. SAB-142 is in development as a novel, potentially best-in-class, disease-modifying immunotherapeutic approach to treat stage 3 T1D by delaying the progression of disease.

NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Meredith & The Media, a media publication focused on media industry news and exclusive interviews with journalists, today announced the appointment of former Adweek editor David Cohen as editor and the launch of a new Friday Media Lunch Series in partnership with Coffee Communications.

Numab to receive milestone payment

PHILADELPHIA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Axalta Coating Systems, Ltd. (Axalta) (NYSE: AXTA), a leading global coatings company, today announced the release of its 2023-2024 Sustainability Report. The report reflects the progress Axalta has made to advance the sustainability of the company’s operations and products, as well as its continued commitment to integrate sustainability into Axalta’s business strategy.

SCHAUMBURG, Ill. and IRVINE, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the second annual CG-SUO-CTC NMIBC Research Fellowship designed to support the development of outstanding clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).

WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2025 at 1:30 PM PT.

ORLANDO, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- PureCycle Technologies, Inc. (Nasdaq: PCT), a U.S.-based company revolutionizing plastic recycling, announced today the appointment of Valerie Mars to its Board of Directors, effective January 1, 2026. Mars was previously the Senior Vice President and Head of Corporate Development at Mars, Incorporated, a function she led for over 20 years.

Company secures first purchase order and multi-year commitment at Ireland’s largest electrophysiology center

CALGARY, Alberta, Dec. 18, 2025 (GLOBE NEWSWIRE) -- DIRTT Environmental Solutions Ltd. (TSX: DRT; OTCQX: DRTTF) ("DIRTT" or the "Company"), a leader in industrialized construction, announced today that the Toronto Stock Exchange ("TSX") has accepted DIRTT's notice of intention to renew its normal course issuer bid (the "Renewed NCIB") for common shares in the capital of DIRTT ("Common Shares"). The Renewed NCIB is expected to commence on December 22, 2025, following the expiry of the Company's current NCIB (the "Prior NCIB") on December 19, 2025, and terminate on December 21, 2026.

Company’s USDA Organic Herbs Align with Shared Commitment to Freshness and Sustainability

Multi-pillar growth plan focused on vertical expansion, sales and marketing, partnerships, and selective acquisitions

        ATLANTA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Alan Gould today joins Gray Media, Inc. as Vice President, Investor Relations. He will lead the company’s efforts to strengthen its relationships with the investment community through the quarterly earnings process and expanded ongoing engagement with current and prospective investors.

Independent reporting exposes enterprise chatbots discussing sex toys, magic mushrooms, and Nazis, underscoring why generic, hallucination-prone LLMs are unfit for live commerce

The LOI Aligns with Federal Priorities on Fentanyl Crisis, Artificial Intelligence, and Quantum Technology

On track for interim analysis in late January 2026 and topline final results November 2026

New Residual Structure Improves Capital Efficiency

Mobix Labs Expected to Deliver 54% Year-Over-Year Revenue Growth with Significant Margin Expansion and Reduced Operating Losses

The island-wide special customs operations at the Hainan Free Trade Port (FTP) in south China were officially launched on Thursday. CGTN published an article highlighting how the port's preferential policies will further stimulate business investment, facilitate cross-border flows of goods and production factors, and position Hainan as a key hub connecting domestic and international markets. 

The in-app gamified financial literacy program gains traction as users look to Sezzle as an all-in-one platform for shopping, rewards, and financial education.

VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB US: DMGGF) (FRANKFURT: 6AX) (“DMG”), a vertically integrated blockchain and data center technology company, today announces its fiscal fourth quarter and full year audited 2025 financial results. All financial references are in Canadian Dollars unless specified otherwise. Readers are encouraged to review the Company’s September 30, 2025 full year audited financial statements and management’s discussion and analysis thereof for an assessment of the Company’s performance and applicable risk factors, available at www.sedarplus.ca.

Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease

NEW YORK and SEOUL, South Korea, Dec. 18, 2025 (GLOBE NEWSWIRE) -- K Wave Media (Nasdaq: KWM), a Korean cultural innovation and digital asset company, today provided a corporate update summarizing recent milestones and announcing a significant regulatory achievement that strengthens its capital strategy and growth trajectory.

Fourth Quarter Fiscal 2025 Summary(All comparisons are year-over-year unless otherwise noted)

Terra Innovatum Global Recognized for Thought Leadership, Advancing Energy Equity, and Global Access to Clean Power Through its SOLO™ Micro-Modular Nuclear Reactor

EDMONTON, Alberta, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Regenx Tech Corp., (the "Company" or "Regenx") (CSE: RGX) (OTCQB: RGXTF) (FSE: YRS WKN: A2DSW3) is pleased to announce that it is receiving advisory services and funding of up to $55,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). This marks the company’s second project supported by NRC IRAP.

CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or the “Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the pricing of its underwritten offering of 5,000,000 shares of its common stock at a price of $6.00 per share. The gross proceeds to the Company from this offering are expected to be $30.0 million, before deducting underwriting discounts and commissions and other offering expenses.

WILMINGTON, Del., Dec. 18, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has repaid the remaining $5.4 million balance sheet debt to Anson Funds, LLC, through equity conversion of common stock. There were no warrants or other repricing mechanisms associated with this transaction. Anson originally lent $16.2 million USD to the Company to fund repayment of prior loans and corporate operating expenses. With this repayment, the Company anticipates ending the 2025 calendar year with a balance sheet free of all debt. NRx believes that this milestone properly positions the company’s capital structure for accelerated growth with anticipated drug approvals and clinic expansions in the coming year.

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations

SAN MATEO, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced positive results in the Phase 1 pharmacokinetic (PK) trial of a combination of its oral once-daily fatty acid synthase (FASN) inhibitor, denifanstat, and a thyroid hormone receptor beta (THR-β) agonist, resmetirom.

VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) (“Hydreight” or the “Company”), a leading provider of compliant digital health infrastructure and on-demand healthcare services across the United States, is pleased to provide an update on the Company’s recent operational performance and platform activity.

BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management plans to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 11:15 a.m. PST / 2:15 p.m. EST.

Miami, FL, Dec. 18, 2025 (GLOBE NEWSWIRE) -- ONAR Holding Corporation (OTCQB: ONAR) (“ONAR” or the “Company”), an AI-powered marketing platform and network of specialist agencies, today announced that it has retired approximately $311,000 of outstanding debt through a voluntary conversion into ONAR common stock by certain noteholders.

Prescription pharmaceutical transdermal fentanyl is a valuable treatment for management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment for which alternate treatment options are inadequate.

SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14, 2026, at 2:15 p.m. PT.

NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Quartz Mountain Resources Ltd. (TSX-V: QZM; OTCQX: QZMRF), a company focused on discovering and transacting important-scale gold, silver and copper projects in British Columbia, has qualified to trade on the OTCQX® Best Market. Quartz Mountain Resources Ltd. upgraded to OTCQX from the OTCQB® Venture Market.

BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced positive preliminary data from its ongoing Phase 1 clinical studies evaluating micvotabart pelidotin (MICVO), a first-in-concept antibody-drug conjugate (ADC) targeting extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM), in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The update includes preliminary data from both the Phase 1 monotherapy study in 2L+ R/M HNSCC and the Phase 1/2 study evaluating MICVO in combination with Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy, pembrolizumab, in 1L/2L+ R/M HNSCC.

Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint

TORONTO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX: TSK, OTCQX: TSKFF) announces that further to the Company’s news release of December 17, 2025, the Company has successfully reduced staffing levels at the Bralorne Mine in accordance with its Emergency Response Plan in response to restricted site access caused by an extreme rainfall event in the region. All but 16 critical personnel drove out via Highway 40 which was temporarily opened to facilitate the withdrawal of non-critical staff and contractors. Ministry of Transportation and Transit in British Columbia will conduct a geotechnical stability evaluation today and will advise on the expected timeline to partially or fully open the road. The Company will provide further updates as new information becomes available.

Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases

New RentRedi Awards honor smart rental owners and property managers that achieved the most successful rental businesses

Combined company expects to site and commence construction of the first utility-scale fusion power plant in 2026 

CHANTILLY, Va., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) announced today that the company was awarded a seat on the U.S. Air Force Comprehensive Construction & Engineering Multiple Award Task Order Contract (MATOC). Managed by the Air Force Civil Engineering Center (AFCEC), this $15 billion ceiling value contract will ensure the readiness and resilience of U.S. Air Force and Department of War facilities. Work will be performed globally, with an initial five-year ordering period and five one-year options.

TORONTO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- NorthWest Copper Corp. (“NorthWest” or the “Company”) (TSX-V: NWST) is pleased to report drill results from two holes completed as part of its 2025 program at the Company’s 100% owned Kwanika project in British Columbia. Both holes returned higher-grade1 results, highlighted by an intercept in hole K-25-283 within the Central Zone of 43 metres grading 1.83% Cu and 1.28g/t Au (3.01% copper equivalent2, “CuEq”), and a significant near-surface intercept in K-25-273 of 123 metres grading 1.31% Cu and 0.83g/t Au (2.09% CuEq).

TORONTO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Goliath Resources Limited (TSX-V: GOT) (OTCQB: GOTRF) (FSE: B4IF) (the “Company” or “Goliath”) is pleased to report Rob McEwen a cornerstone strategic investor has increased his direct ownership by exercising all of his warrants for total proceeds of $1,214,285. This exercise takes Rob’s direct ownership to 4,445,142 common shares of the Company representing 2.6% of the total issued and outstanding shares.

Vantage Acquisition Anchors HHH’s Transformation into a Diversified Holding Company 

LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient enrollment in the randomized, placebo-controlled Phase 2 clinical trial, the OXTOX study (Oxaliplatin Neurotoxicity study in patients with metastatic colorectal cancer). This study, an investigator-initiated clinical trial led by Dr. Janette Vardy and Dr. Haryana Dhillon, is evaluating MN-166 (ibudilast) for the prevention of chemotherapy-induced peripheral neuropathy in patients with metastatic colorectal cancer. A total of 100 patients have been randomized across two treatment arms at 11 clinical sites in Australia. Patient recruitment is now officially closed.

Dubai, December 18, 2025 – VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or “the Company”), announces that at the opening of trading today, its American Depositary Shares (ADSs) listing will be transferred to the Nasdaq Global Select Market of the Nasdaq Stock Market (“Nasdaq”).

NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Salus GRC, a governance, risk, and compliance consultancy backed by Charlesbank Capital Partners and led by a team of industry veterans, today announced a strategic partnership with Broad-Gauge, a provider of workforce intelligence for private equity firms and middle-market companies. With deep expertise across regulatory compliance, cybersecurity, and operational risk—and the institutional support of Charlesbank—Salus GRC is expanding its ability to deliver integrated, data-driven insight to private equity clients seeking stronger oversight and value creation across their portfolios.

HOUSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- KBR (NYSE: KBR) announced today it has been awarded a seat on a multiple award, indefinite delivery indefinite quantity (IDIQ) contract by the U.S. Naval Supply Systems Command (NAVSUP). The NAVSUP Worldwide Expeditionary Multiple Award Contract (WEXMAC) 2.1 Territorial Integrity of the United States (TITUS) is a contract for readiness and sustainment focused on defense of the continental United States.

Goranson Bain Ausley (GBA), the largest family law firm in Texas, has expanded its Austin office with the promotion of Kristiana Butler and Angelica Rolong Cormier to Partner and the addition of Lauren Restino as Associate Attorney. The expansion reflects the firm’s continued commitment to serving families and professionals across Central Texas, including those in Austin’s growing tech, healthcare, financial services, and creative sectors.

HAIKOU, China, Dec. 18, 2025 (GLOBE NEWSWIRE) -- China on Thursday launched island-wide special customs operations in the Hainan Free Trade Port (FTP), the world's largest FTP by area, allowing freer entry of overseas goods, expanding zero-tariff coverage and more business-friendly measures.

The Magnum Ice Cream Company N.V.

HONG KONG, Dec. 18, 2025 (GLOBE NEWSWIRE) -- The recent AI Agent Expo, hosted by AIsmiley in Tokyo, set new attendance records and highlighted the booming demand for AI-powered digital transformation (DX) in Japan. Among all enterprise priorities, AI customer support stood out as the most urgent need. GPTBots.ai’ advanced solutions attracted strong interest from leaders in manufacturing, finance, technology, and consumer goods, reflecting the rapid acceleration of intelligent automation across Japanese industries.

ORLANDO, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- What started as a tiki bar idea turned into an award-winning showstopper.

 

BRATISLAVA, Slovakia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- ESET Research has discovered a new China-aligned APT group, LongNosedGoblin, that abuses Group Policy – a mechanism for managing settings and permissions on Windows machines, typically used with Active Directory – to deploy malware and move laterally across the compromised network. It is used to deploy cyberespionage tools across networks of governmental institutions in Southeast Asia and Japan. In 2024, ESET researchers noticed previously undocumented malware in the network of a Southeast Asian governmental entity. However, the group has been active since at least since September 2023. As of this September, ESET began observing renewed activity by the group in the region. It deploys malware across the compromised network, and cloud services (e.g., Microsoft OneDrive and Google Drive) for Command & Control (C&C).

MAINZ, Germany, December 18, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, or “the Company”) today announced the closing of its acquisition of CureVac N.V. (Nasdaq: CVAC, “CureVac”) and that the subsequent offering period (the “Subsequent Offering Period”) of the exchange offer (the “Offer”) for all outstanding shares of CureVac expired today at 12:01 a.m. Eastern Time. With the successful acquisition, BioNTech intends to further complement its capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing. The acquisition builds on BioNTech’s proven track record and established position in the global mRNA industry and supports the execution of the Company’s oncology strategy which focuses on two pan-tumor programs: mRNA-based cancer immunotherapy candidates, and pumitamig (BNT327/BMS986545), a bispecific antibody candidate targeting PD-L1 and VEGF-A, which is being jointly developed with Bristol Myers Squibb Company (NYSE: BMY, “BMS”).

Recognition highlights Temenos’ market impact, vision and capabilities in delivering customer experience orchestration products for banks and wealth managers

DENVER, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SHF Holdings, Inc., d/b/a Safe Harbor Financial (Safe Harbor or the “Company”) (Nasdaq: SHFS), a fintech leader in providing financial services and credit facilities to the regulated cannabis industry, issued the following statement regarding the potential federal rescheduling of cannabis.

Basel, Switzerland – December 18, 2025 – FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, today announced the close of an insider-led USD 50 million (CHF 40 million) Series A financing. The funding will be used to advance Phase 1 clinical development of its lead drug candidate, FORX-428, a potential best-in-class PARG (poly (ADP-ribose) glycohydrolase) inhibitor designed to target and disrupt the DNA Damage Response (DDR) in advanced solid tumors.